2026 ICD-10-CM Diagnosis Code C96.9Malignant neoplasm of lymphoid, hematopoietic and related tissue, unspecified
ICD-10-CM Codes›C00–D49›C81-C96›C96
- Billable — Valid for Submission
- Chronic Condition
C96.9 is a billable ICD-10-CM diagnosis code for malignant neoplasm of lymphoid, hematopoietic and related tissue, unspecified. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026) and groups to MS-DRG 820 through 825, 840 through 842. Coders also document this condition as arthritis secondary to hematological malignancy. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Non-Hodgkin lymphoma.
Code Identity
Code Classification
Approximate SynonymsGuidance
Alternate terms and clinical phrases that map to this code.
- Arthritis secondary to hematological malignancy
- Arthritis secondary to malignancy
- Erythropoietic uroporphyria associated with myeloid malignancy
- Malignant neoplasm of lymphoid, hematopoietic and/or related tissue
- Myeloid and/or lymphoid neoplasm with PCM1-JAK2
- Neurolymphomatosis
- Paraneoplastic neuropathy
- Paraneoplastic peripheral neuropathy
- Porphyruria
- Uroporphyrinuria
Clinical ClassificationClinical
AHRQ’s CCSR groups this code into broader clinical categories.
Clinical InformationClinical
Herpesvirus 2, Gallid
the type species of the genus mardivirus in the family herpesviridae. it is the etiologic agent of marek disease, infecting domestic fowl and wild birds.Neurolymphomatosis
infiltration of the nervous system by malignant lymphoma cells.
Table of NeoplasmsClinical
Anatomical sites in the Table of Neoplasms that reference this code family.
| Site | Malig. Primary | Malig. Secondary | Ca in situ | Benign | Uncertain | Unspec. |
|---|---|---|---|---|---|---|
| bone (periosteum) › marrow NEC (any bone) | C96.9 | C79.52 | – | – | D47.9 | D49.89 |
| hematopoietic, hemopoietic tissue NEC | C96.9 | – | – | – | – | – |
| lymph, lymphatic channel NEC › gland (secondary) › primary (any site) NEC | C96.9 | – | – | – | – | – |
| lymph, lymphatic channel NEC › node [See Also: Neoplasm, lymph gland] | C96.9 | – | – | – | – | – |
| lymph, lymphatic channel NEC › node [See Also: Neoplasm, lymph gland] › primary NEC | C96.9 | – | – | – | – | – |
| marrow (bone) NEC | C96.9 | C79.52 | – | – | D47.9 | D49.89 |
| spine, spinal (column) › marrow NEC | C96.9 | C79.52 | – | – | D47.9 | D49.89 |
| vertebra (column) › marrow NEC | C96.9 | C79.52 | – | – | D47.9 | D49.89 |
Patient EducationClinical
Lymphoma
Lymphoma is a cancer of a part of the immune system called the lymph system. There are many types of lymphoma. One type is Hodgkin disease. The rest are called non-Hodgkin lymphomas.
Read the full article at MedlinePlus
Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.
Convert C96.9 to ICD-9-CMHistory
The closest ICD-9-CM equivalents under the General Equivalence Mappings.
Code HistoryHistory
Questions About C96.9Overview
Is C96.9 a billable code?
Yes. This is a billable ICD-10-CM code, specific enough to report malignant neoplasm of lymphoid, hematopoietic and related tissue, unspecified on HIPAA-covered claims from October 1, 2025 through September 30, 2026.
What MS-DRG does C96.9 group to?
When malignant neoplasm of lymphoid, hematopoietic and related tissue, unspecified is the principal diagnosis on an inpatient stay, it groups to MS-DRG 820, 821, 822, 823, 824, 825, 840, 841, 842, with relative weights from 1.0104 to 5.8648 depending on complications. Higher weights mean higher Medicare reimbursement.
What is the ICD-9 equivalent of C96.9?
Under the General Equivalence Mappings, malignant neoplasm of lymphoid, hematopoietic and related tissue, unspecified converts to ICD-9-CM 202.90 (unsp lym unsp xtrndl org), 202.91 (lymphoid mal NEC head), and 202.92 (lymphoid mal NEC thorax). The mapping is approximate, so confirm the match fits the documentation.
Footnotes
[1] Chronic - a chronic condition code indicates a condition lasting 12 months or longer and its effect on the patient based on one or both of the following criteria:
- The condition results in the need for ongoing intervention with medical products,treatment, services, and special equipment
- The condition places limitations on self-care, independent living, and social interactions.
